Verduin C M, Jansze M, Hol C, Mollnes T E, Verhoef J, van Dijk H
Eijkman-Winkler Institute of Medical and Clinical Microbiology, Utrecht University Medical Faculty, University Hospital, The Netherlands.
Infect Immun. 1994 Feb;62(2):589-95. doi: 10.1128/iai.62.2.589-595.1994.
The mechanism of resistance to human complement-mediated killing in Moraxella catarrhalis was studied by comparing different complement-sensitive and complement-resistant M. catarrhalis strains in a functional bystander hemolysis assay and an enzyme-linked immunosorbent assay (ELISA) for soluble terminal complement complexes. Complement-resistant stains appeared to activate complement to the same extent as, or even slightly better than, complement-sensitive strains. This indicates that complement-resistant strains do not inhibit classical or alternative pathway activation but interfere with complement at the level of membrane attack complex formation. A clear difference in dose-response curves for resistant and sensitive strains was observed both in the bystander hemolysis assay and in the ELISA. Complement-resistant strains showed optimum curves, whereas complement-sensitive strains gave almost linear curves. We conclude that resistant strains bind and/or inactivate one of the terminal complement components or intermediates involved in membrane attack complex formation. Trypsin, known to abolish complement resistance, changed the optimum dose-response curve of a resistant strain to a linear one, which strongly suggests that complement resistance is mediated by an M. catarrhalis-associated protein. This protein acts directly or through the binding of a terminal complement inhibitor present in serum.
通过在功能性旁观者溶血试验和用于可溶性末端补体复合物的酶联免疫吸附测定(ELISA)中比较不同的对补体敏感和补体耐药的卡他莫拉菌菌株,研究了卡他莫拉菌对人补体介导杀伤的耐药机制。补体耐药菌株激活补体的程度似乎与补体敏感菌株相同,甚至略好于补体敏感菌株。这表明补体耐药菌株不抑制经典或替代途径的激活,而是在膜攻击复合物形成水平干扰补体。在旁观者溶血试验和ELISA中均观察到耐药菌株和敏感菌株的剂量反应曲线存在明显差异。补体耐药菌株呈现最佳曲线,而补体敏感菌株给出的几乎是线性曲线。我们得出结论,耐药菌株结合和/或灭活参与膜攻击复合物形成的一种末端补体成分或中间体。已知能消除补体耐药性的胰蛋白酶将耐药菌株的最佳剂量反应曲线变为线性曲线,这强烈表明补体耐药性是由卡他莫拉菌相关蛋白介导的。该蛋白直接发挥作用或通过结合血清中存在的末端补体抑制剂发挥作用。